3 results
BioXmark liquid fiducial to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial
To test the feasibility and accuracy of BioXmark fiducial markers for IGRT based rectal tumor boosting.
Approved WMORecruiting
The proposed multi-center population-based open-label randomized controlled trial with blinded outcome assessment will examine if metformin slows AAA growth in patients with small AAAs who do not have diabetes. Primary objective To examine if up to…
Approved WMORecruiting
Phase 1: • To determine the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors, including ALK+ IMT.• To characterize the PK of brigatinib administered as monotherapy in…